Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Phytomedicine ; 109: 154618, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36610137

ABSTRACT

BACKGROUND: Tumor cells reprogram their metabolic network to maintain their uncontrolled proliferation, metastasis, and resistance to cancer therapy. Treatments targeting abnormal cellular metabolism may have promising therapeutic effects. Formosanin C (FC), a diosgenin derived from the rhizoma of Paris polyphylla var. yunnanensis, has shown potent anti-cancer activities against various cancer types. However, the effect of FC on cancer metabolism remains to be elucidated. PURPOSE: In this research, we aimed to elucidate FC's effect and potential mechanisms on metabolism in lung cancer. METHODS: Colony formation, transwell cell migration, and apoptosis were detected in multiple NSCLC cell lines to assess the cytotoxicity of FC. 1H NMR metabolomics approach was applied to screen the differential metabolites in H1299 cells and the culture medium. Western blotting, flow cytometry, and other molecular biological techniques were performed to verify the latent mechanism involved in metabolites. An allograft tumor model was employed to investigate the anti-tumor effects of FC in vivo. RESULTS: FC significantly inhibited monoclonal formation and migration and induced cell cycle arrest and apoptosis in NSCLC cells. FC altered the abundances of 12 metabolites in lung cancer cells and 3 metabolites in the medium. These differential metabolites are primarily involved in glycolysis, citric acid cycle, and glutathione pathways. Notably, there was a remarkable increase in intracellular lactate and a reduction in extracellular lactate after FC treatment. Mechanically, FC downregulated the expression of MCT4 and CD147, blocking the export of lactate. Furthermore, FC also evoked mitochondrial dysfunction coupled with excessive oxidative stress, decreased mitochondrial membrane potential, ATP production reduction, glutathione depletion, and Ca2+ overload. Moreover, FC suppressed tumor progression in vivo with reduced protein levels of the MCT4 and CD147 in tumor tissues. CONCLUSION: FC inhibits lung cancer growth by the novel mechanism in which MCT4/CD147-mediated inhibition of lactate transport and disruption of mitochondrial functions are involved.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Diosgenin , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/drug therapy , Cell Line, Tumor , Cell Proliferation , Diosgenin/pharmacology , Lactic Acid/metabolism , Lung Neoplasms/drug therapy , Monocarboxylic Acid Transporters/metabolism
2.
Pharmacol Res ; 185: 106487, 2022 11.
Article in English | MEDLINE | ID: mdl-36202184

ABSTRACT

Alterations in histone modification have been linked to cancer development and progression. Celastrol, a Chinese herbal compound, shows potent anti-tumor effects through multiple signaling pathways. However, the involvement of histone modifications in this process has not yet been illustrated. In this study, barcode sequencing of a eukaryotic genome-wide deletion library revealed that histone modifications, especially histone acetylation associated with the NuA4 histone acetyltransferase complex, were involved in the anti-proliferation actions of celastrol. The essential roles of histone modification were verified by celastrol sensitivity tests in cells lacking specific genes, such as genes encoding the subunits of the NuA4 and Swr1 complex. The combination of celastrol and histone deacetylase inhibitors (HDACi), rather than the combination of celastrol and histone acetyltransferase inhibitors, synergistically suppressed cancer cell proliferation. In addition to upregulating H4K16 acetylation (H4K16ac), celastrol regulates H3K4 tri-methylation and H3S10 phosphorylation. Celastrol treatment significantly enhanced the suppressive effects of HDACi on lung cancer cell allografts in mice, with significant H4K16ac upregulation, indicating that a combination of celastrol and HDACi is a potential novel therapeutic approach for patients with lung cancer.


Subject(s)
Histone Deacetylase Inhibitors , Lung Neoplasms , Mice , Animals , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylase Inhibitors/therapeutic use , Acetylation , Histones/metabolism , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Histone Acetyltransferases/metabolism , Histone Acetyltransferases/therapeutic use
3.
J Nanosci Nanotechnol ; 15(11): 9246-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26726676

ABSTRACT

A blue organic light-emitting diode with a double hole-transporting (DHT) structure has been developed. The device, ITO/N,N'-Bis (naphthalene-1-yl)-N,N'-bis(phenyl)-benzidine/4,4'-Bis (N-carbazolyl)-1,1'-biphenyl (CBP)/4,4'-Bis(2,2-diphenylethen-yl) diphenyl/CBP/tris(8-hydroxyquinolate)aluminum/lithium fluoride/aluminum, consists of a hole-transporting layer, a DHT structure layer and an electron-transporting layer. The blue color purity is improved by modulation the thickness of CBP layer. When the thicknesses of left CBP and right CBP are respectively 8 nm and 2 nm, the more pure blue coordinates (0.155, 0.079) are obtained at 9 V, which are very close to the national television system committee standard blue coordinate (0.14, 0.08). Furthermore the current density, brightness and the luminous efficiency of device with the left CBP of 8 nm and the right CBP of 2 nm are respectively 144.7 mA/cm2, 1065 cd/m2 and 0.93 cd/A at voltage of 9 V.

SELECTION OF CITATIONS
SEARCH DETAIL
...